'Cardiac toxicity' presentation slideshows

Integration of Taxanes in the Management of Breast Cancer

Integration of Taxanes in the Management of Breast Cancer. Jean-Marc A. Nabholtz, MD, MSc Professor of Medicine, Univ. of California at Los Angeles Director, Cancer Therapy Development Program Director, Solid Tumor Program, Jonsson Comprehensive Cancer Center, UCLA Chairman, CIRG and BCIRG.

572 views • 46 slides

CARDIAC TOXICITY OF CANCER THERAPEUTIC AGENTS

CARDIAC TOXICITY OF CANCER THERAPEUTIC AGENTS. Dr Binjo J Vazhappilly Senior Resident. New anticancer therapies have led to long life expectancy for many patients. Treatment related co morbidities have become an issue for cancer survivors.

609 views • 45 slides

CARDIAC TOXICITY OF CANCER THERAPEUTIC AGENTS

CARDIAC TOXICITY OF CANCER THERAPEUTIC AGENTS. Dr Binjo J Vazhappilly Senior Resident. New anticancer therapies have led to long life expectancy for many patients. Treatment related co morbidities have become an issue for cancer survivors.

453 views • 45 slides

Artemisia BioMedical , Inc The Discovery of Artemisinin

1.07k views • 40 slides

TCA mechanisms of Toxicity

Anti-cholinergic Na+ channel blockade K+ channel blockade Alpha 1 antagonism Serotonin reuptake inhibition GABA antagonism. Anticholinergic toxidrome Wide QRS Prolonged QT Hypotension Seritonin syndrome Seizures. TCA mechanisms of Toxicity. Anticholinergic Toxidrome.

767 views • 32 slides

Biomarkers of Exposure to Hazardous Substances (2017-2022)

Biomarkers of Exposure to Hazardous Substances (2017-2022). The UC Davis Superfund Research Center conducts research to: Improve understanding of the mechanisms by which hazardous chemicals produce adverse health affects,

318 views • 31 slides

Applications of Lead aVR

Applications of Lead aVR. ECG Rounds February 15, 2007 James Huffman, PGY-1. Outline. Background Discussion and Practice LMCA occlusion Acute Pericarditis TCA Cardiotoxicity Preexcitation syndrome tachycardia Review. Background on lead aVR. Augmented unipolar limb lead

413 views • 27 slides

Title 1 Subtitle 2

Chemotherapy Induced Cardiac Toxicity Russell Huntsinger, MD Cardiologist. Title 1 Subtitle 2. What is Cardiac Toxicity?. Damage to the heart muscle by a toxin is called cardiac toxicity. They may cause arrhythmias May lead to heart failure

250 views • 22 slides

Dottor Liberato Di Lullo Direttore U.O.C. DI ONCOLOGIA

228 views • 22 slides

Giuseppe Biondi Zoccai, MD University of Modena and Reggio Emilia gbiondizoccai@gmail

Non-pegylated liposomial doxorubicin is less cardiotoxic than epirubicin in women with breast cancer: evidence from the LITE randomized study. Giuseppe Biondi Zoccai, MD University of Modena and Reggio Emilia gbiondizoccai@gmail.com

368 views • 21 slides

Informing Care Decisions: Emerging Technologies, Scientific Evidence, and Communication

Informing Care Decisions: Emerging Technologies, Scientific Evidence, and Communication. Elise Berliner, PhD Director, Technology Assessment Program Center for Outcomes and Evidence. http://blogs.amctv.com/scifi-scanner/2009/01/star-trek-ultrasonic-medical-device.php.

305 views • 19 slides

A young man in a coma

A young man in a coma. PBL Neuro Block Week Three.

216 views • 13 slides

BREAST CANCER Neoadjuvant Chemotherapy

BREAST CANCER Neoadjuvant Chemotherapy. Interest of neoadjuvant CT. % of patients with distant relapse. Tumor N. of nodes diameter 0 1-3 > 3 1.9 cm 21 26 - 3.2 cm 18 48 58 4.2 cm 32 58 74 6.2 cm 32 71 79 9 cm 62 - - . Need for a systemic treatment even in small tumors.

862 views • 11 slides

BREAST CANCER Neoadjuvant Chemotherapy

BREAST CANCER Neoadjuvant Chemotherapy. Interest of neoadjuvant CT. % of patients with distant relapse. Tumor N. of nodes diameter 0 1-3 > 3 1.9 cm 21 26 - 3.2 cm 18 48 58 4.2 cm 32 58 74 6.2 cm 32 71 79 9 cm 62 - - . Need for a systemic treatment even in small tumors.

780 views • 11 slides

Cardiac Toxicity

Cardiac Toxicity. Objective. The learner will be able to describe cardiac toxicity, including its major causes, assessment, and management. Causes. Chemotherapy

815 views • 11 slides

Presented by Frank Sistare, Ph.D. at the Nonclinical Studies Subcommittee of the

Presented by Frank Sistare, Ph.D. at the Nonclinical Studies Subcommittee of the Advisory Committee for Pharmaceutical Science March 9, 2000. Accessible Toxicity Biomarker Morning Presentations.

198 views • 10 slides

Crown J et al. Proc SABCS 2010;Abstract P5-10-17.

Bevacizumab (Bev) in Combination with Docetaxel (T) and Cyclophosphamide (C) as Adjuvant Treatment (AdjRx) for Patients (Pts) with Early Stage (ES) Breast Cancer (BrCa) and Normal HER-2 Status. A Pilot Evaluation. Crown J et al. Proc SABCS 2010;Abstract P5-10-17. Methods.

230 views • 7 slides

Effect of Multi Drug Administration on Cardiac Enzymes and Tissues

In the present study individual and combinations of drugs were given to rabbits for the period of 60 days and their effects on cardiac function and myocytes were observed.

84 views • 7 slides

Abstract:

Vigilant Cardiac Function Monitoring in Childhood Cancer Survivors: A Specialized Team Approach Emily Mueller, MD 1 , Linda Rivard, RN 2,3 , Marc A Silver, MD 4,5 , Pamela Cianci, APN-C 4,5 , Sharon Brennan BSN 4,5 , Sharad Salvi 1,2,3 , Jason Canner, DO 1,2,3

125 views • 1 slides